Genmab (GMAB) Stock Price, Quote, News & History | Benzinga

Genmab (GMAB) Stock Price, Quote, News & History

GMABNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

Trade with Public

$32.63

-0.72-2.16%

At close: Jan 29, 4:00 PM EST

$32.86

-0.49-1.47%

Pre-Market: 8:31 AM EST

Overview

News Earnings Options Guidance Analyst Ratings Short Interest Government Trades Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

-

Close

$32.63

Volume / Avg.

2.39K / 1.75M

Day Range

- - -

52 Wk Range

17.24 - 35.43

Market Cap

$20.24B

P/E Ratio

14.28

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

1.83%

Days to Cover

7.92

Recent Genmab A/S News

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

Genmab shared Phase 3 trial results for epcoritamab in lymphoma, missing overall survival but improving disease control, as analyst weighs approval risks and future trial data.

Vandana Singh

Why Are Investors Paying Attention To Genmab Stock?

Shares of Genmab (NASDAQ: GMAB) are rising Wednesday after the Danish biotechnology company said it would partner with AI company Anthropic.

Alex Perry

Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer

Incyte reported positive results from a trial of tafasitamab as a first-line treatment for adults with DLBCL. No new safety issues were seen.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.23B

Investing Cash Flow (TTM)

5.81M

Financing Cash Flow (TTM)

-422.77M

Free Cash Flow (TTM)

1.16B

Capital Expenditure (TTM)

-69.41M

Net Change in Cash (TTM)

815.23M

Analyst Trends and Forecast

1

Aug 25

2

Sep 25

2

Oct 25

2

Nov 25

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$16.69B

PE Ratio (TTM)

14.28

PE Ratio (FWD)

11.79

PEG Ratio (TTM)

0.62

PS Ratio (TTM)

5.94

PB Ratio (TTM)

3.49

Earnings Yield % (TTM)

7.00%

Earnings Yield % (FWD)

8.48%

EV / EBITDA (TTM)

9.78

Price / EBITDA (TTM)

12.06

Price / Free Cash Flow (TTM)

17.70

Book Value / Share

$9.34

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$11.37M

Total Cash

$1.76B

Debt to Equity

0.02

Issuance of Debt (TTM)

-$11.37M

Repayment of Debt (TTM)

-$11.37M

Key Statistics

Open

-

Close

$32.63

Volume / Avg.

2.39K / 1.75M

Day Range

- - -

52 Wk Range

17.24 - 35.43

Market Cap

$20.24B

P/E Ratio

14.28

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

1.83%

Days to Cover

7.92

About

Sector

Health Care

Industry

Biotechnology

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab...

Show More

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Genmab (GMAB) stock?

A

You can purchase shares of Genmab (NASDAQ:GMAB) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Genmab (GMAB) competitors?

A

Other companies in Genmab’s space includes: Avidity Biosciences Inc (NASDAQ:RNA), BeOne Medicines Ltd (NASDAQ:ONC), Exact Sciences Corp (NASDAQ:EXAS), Neurocrine Biosciences Inc (NASDAQ:NBIX) and Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Q

What is the forecast, or price target, for Genmab (GMAB) stock?

A

Genmab has a consensus price target of $39.40.

Q

What is the current price for Genmab (GMAB)?

A

The stock price for Genmab (NASDAQ: GMAB) is $32.86 last updated February 2, 2026 at 7:04 AM EST.

Q

Does Genmab (GMAB) pay a dividend?

A

There are no upcoming dividends for Genmab.

Q

When is Genmab (NASDAQ:GMAB) reporting earnings?

A

Genmab does not have any upcoming earnings scheduled.

Q

Is Genmab (GMAB) going to split?

A

There is no upcoming split for Genmab.

Q

What sector and industry does Genmab (GMAB) operate in?

A

Genmab is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Avidity Biosciences Inc

BeOne Medicines Ltd

Exact Sciences Corp

Neurocrine Biosciences Inc

Ionis Pharmaceuticals Inc

Roivant Sciences Ltd

United Therapeutics Corp